^
Association details:
Evidence:
Evidence Level:
Sensitive: D – Preclinical
Source:
Title:

CDK4/CDK6-INHIBITION AS A POTENT APPROACH TO AUGMENT ANTI-NEOPLASTIC EFFECTS OF MIDOSTAURIN, AVAPRITINIB AND NINTEDANIB IN KIT D816V+ NEOPLASTIC MAST CELLS

Published date:
05/12/2021
Excerpt:
The pharmacologic CDK4/CDK6-inhibitors palbociclib, ribociclib and abemaciclib were found to suppress proliferation of HMC-1 cells and ROSA cells expressing or lacking KIT D816V…